Takeda Presents P-III Trial (ADVANCE-CIDP 1) Results of Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy at PNS 2023, Published in the JPNS
Shots:
- The P-III trial (ADVANCE-CIDP 1) evaluating Hyqvia as maintenance therapy vs PBO in a ratio (1:1) in 132 adult patients with CIDP and who had remained on a stable dosing regimen of intravenous immunoglobulin (IVIG) therapy for 3mos. prior to screening
- The results showed that the patients treated with Hyqvia achieved a significant reduction in relapse rate (9.7% vs 31.4%), respectively, lower probability of functional worsening rates (37.5% vs 54.4%), patients experienced longer time to relapse with the Kaplan–Meier curves separating early @~4wk., change in R-ODS centile scores −6.1 vs −0.9, respectively
- The safety profile was generally consistent with the existing EU summary of product characteristics. The therapy is currently under regulatory review in the US and EU for use as a maintenance therapy in adult patients with stable CIDP
Ref: Businesswire | Image: Takeda
Related News:- Takeda’s Hyqvia Receives the US FDA’s sBLA Approval for the Treatment of Childrens with Primary Immunodeficiency
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
